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Authors’ Note: At the time of VISTAS acceptance of this paper, the American Psychiatric 
Association (APA) was considering APS (Attenuated Psychosis Syndrome) as a proposed 
diagnosis in the psychotic disorders section of the DSM-5.  The APA recently made the decision 
to not include the new diagnosis with the psychotic disorders and moved it to section III of the 
DSM-5 for more research.  The authors of this paper are supportive of this decision for reasons 
described in the paper.  We do however feel that the paper maintains relevance because the of the 
current rise of early intervention programs for psychotic disorders across the country and the 
ongoing use of the Structured Interview for Psychosis Risk Syndromes (SIPS) tool by counselors 
to identify individuals who may be at risk of psychotic disorders.  
 
 Revisions are underway to release the fifth edition of the Diagnostic and 
Statistical Manual of Mental Disorder, DSM-5, (American Psychiatric Association, 2012) 
One diagnosis that is being considered under the category of Schizophrenia Spectrum and 
other Psychotic disorders is Attenuated Psychosis Syndrome (APS).  APS is considered a 
risk factor for major psychotic disorders such as schizophrenia and bipolar disorder.  This 
article will focus on the role counselors play in the early diagnosis of at-risk patients and 
the importance of an accurate diagnosis. Additionally, the categorization of APS in the 
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DSM is considered in an effort to help prevent inappropriate diagnosis and potential 
resulting treatment failure. A literature review is presented on the diagnosis of APS by 
means of the Structured Interview for Psychosis-Risk Syndrome (SIPS)—currently the 
most heavily used assessment tool in the field for identifying those at-risk for 
schizophrenia spectrum disorders such as the purposed APS—as well as long term 
follow-up of APS patients and their outcomes.  Discussion follows on the importance of 
counselors becoming well versed on the symptoms of APS to prevent inaccurately 
diagnosing this population of patients and potentially causing poor outcomes.   
 
Introduction 
 
 Psychosis in general, and schizophrenia specifically, are among the most 
debilitating and difficult to treat disorders in mental health (Correll, Hauser, Auther, & 
Cornblatt, 2010).  Identifying a patient with at-risk symptoms before the first episode of 
schizophrenia can be invaluable to the patient, clinician, and the community because the 
patient is treated early in the course of the disease where treatment is highly effective.  
After years of research it has been confirmed that at-risk symptoms for schizophrenia 
generally precede the first episode of psychosis, which results in the diagnosis of 
schizophrenia (Correll et al., 2010).  At present however, the assessment and recognition 
of these symptoms for schizophrenia or APS remain under debate (Carpenter, 2009).   
 Research has shown that utilizing low dose antipsychotic medication, cognitive 
behavioral therapy, and having a supportive family and social environment are essential 
resources to recovery and reduction of trauma for a patient experiencing symptoms of 
APS (Lencz, Smith, Auther, Correll, & Cornblatt, 2003; McGlashan, Walsh, & Woods, 
2010; Olsen & Rosenbaum, 2006; Portland Identification and Early Referral Program, 
2009; S.Trevino, personal communication, November 18, 2010).  At this time research 
shows that early detection of APS symptoms can achieve secondary and tertiary 
prevention, such as delaying the onset of psychosis and reducing suicide, but does not 
prevent schizophrenia from occurring (McGlashan, et al., 2010.) 
There are various ways in which counselors can receive referrals to assess a 
patient for APS.  The patient can be referred by a family member, a health care provider, 
a school administrator, a court order, another clinician, or by the patient directly. A 
clinical assessment encounter with the patient is then needed.  The encounter should use a 
multi-method approach of clinical interviewing and assessment tests to diagnose and help 
place the patient in the appropriate treatment algorithm.  At first referral to a clinician, the 
patient may not present with a need to assess for APS.  Recognizing a broad marker for 
instability, such as multiple AXIS I diagnoses without clear criteria, may be an effective 
first clue that a patient may be exhibiting APS symptoms and warrant a diagnostic 
assessment. 
 One goal of this paper is to describe the current diagnostic tools for APS, 
especially the Structured Interview for Psychosis-Risk Syndrome, SIPS, (McGlashan, et 
al., 2010). The SIPS assessment tool is a comprehensive assessment tool that can be used 
in the field to diagnose early detection for schizophrenia and monitor symptom severity.   
Evaluating the inclusion criteria of APS into the DSM-5 under the diagnostic 
category of Schizophrenia Spectrum and other Psychotic Disorder is another purpose of 
this paper. Based on recent information provided by the American Psychiatric 
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Association’s Task Force on DSM-5, dated April 27, 2012, the diagnosis of APS has 
been recommended for further research and proposed for Section III of the DSM-5. The 
authors agree with the direction that the DSM-5 task force has taken to require further 
research in this important diagnosis. Creating a diagnosis that treats prodromal psychosis 
as a precursor to schizophrenia and not a precursor for other well recognized disorders 
with psychotic features such as bipolar, trauma, and stressor-related disorders is a 
disservice and dangerous to the patient. 
 
Literature Review 
 
The SIPS is to be administered by trained clinicians of many mental health 
disciplines including clinicians and clinical researchers possessing at least a bachelor’s 
degree (McGlashan et al., 2010).  Tables 1-3, created by the present authors, summarizes 
what the SIPS assessment tool aims to achieve in assessing for and diagnosing APS based 
on The Psychosis-Risk Syndrome: Handbook for diagnosis and follow up (McGlashan et 
al., 2010). The SIPS is a semi-structured interview that is given by a clinician to a patient 
and their family members.  The assessment process may take from 1 to 3 hours.    
 Clinicians administer the SIPS in three stages.  The first section is the Presence of 
Psychotic Symptoms criteria (POPS) and is administered to rule out current or past 
psychosis in a patient.  The second stage of the SIPS is the Criteria of Psychosis Risk 
Syndrome (COPS).  It aims to identify if the patient exhibits one or more symptoms of 
the three types of Psychosis Risk Syndrome (PRS): Brief Intermittent Psychotic 
Syndrome, Attenuated Positive Symptom Syndrome (which is most similar to the criteria 
for the proposed DSM-5 APS diagnosis), and Genetic Risk and Deterioration Syndrome.  
The third section, the Scale of Psychosis Risk Syndrome (SOPS), assesses the rate and 
severity of the PRS.  The SOPS scale is listed first, in Table 1, which is out of sequence 
with the administering stages because the SOPS scale is used to evaluate the POPS and 
COPS.   
The reliability and predictive validity of the SIPS tools has been researched 
(Correll et al., 2010; Lencz et al., 2003; McGlashan et al., 2010; Miller et al., 2003; Olsen 
& Rosenbaum, 2006). In a reliability study done by Miller et al. in 2002, raters 
administering the SIPS were 93% consistent in their assessment of whether subjects were 
at a baseline prodromal or non-prodromal state. The study listed the validity of the SIPS 
tools to predict patients developing a first episode of schizophrenia after baseline 
assessment of psychosis risk syndromes including APS.  Predicting the onset of 
schizophrenic psychosis within 6 months after baseline the SIPS had an accuracy of 46% 
and 54% at 12 months. 
 
Discussion 
 
Accurate and early diagnosis of APS is critical to treating the patient 
appropriately and in obtaining the best therapeutic results. Currently a broad diagnosis of 
psychotic disorder not otherwise specified in the DSM-IV-TR is most often used when 
treating this APS population (American Psychiatric Association, 2000).  However a 
psychotic disorder not otherwise specified diagnosis may not be specific enough to make 
treatment recommendations.  Early recognition research has shown that patients 
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designated as at risk for psychosis can develop a range of diagnoses such as 
schizophrenia, bipolar disorder, post traumatic stress disorder, substance induced 
psychosis, or have no diagnosis (Rossler et al., 2001). Each of these diagnoses carries a 
different treatment protocol. If a new category is to be created in the DSM-5 for 
Attenuated Psychosis Syndrome (McGlashan, et al., 2010), attention should be drawn to 
broadening the differential diagnosis assessment to prevent over or inaccurately 
diagnosing patients with APS and then subsequently inaccurately diagnosing those 
patients with a major psychosis syndrome. This is especially true with the ultimate 
diagnosis of schizophrenia in a patient who may have another cause of psychosis such as 
bipolar disorder. 
A strong therapeutic alliance between the patient and clinician is also important to 
correctly assess for APS symptoms (McGlashan et al., 2010; Wong et al., 2009) and 
result in the potential for a more accurate diagnosis.  If a patient does not feel safe in 
sharing their experiences with the clinician during evaluation, the results will not be 
accurate. A clinician’s role is to help the patient in the reduction of trauma; therefore the 
clinician must use any assessment tool with sensitivity and patient focused actions in 
developing a therapeutic alliance.   
There are over six assessment tools existing today that clinicians can use to 
identify APS symptoms (Olsen & Rosenbaum, 2006).  The two most heavily used in the 
field are the Comprehensive Assessment of At-Risk Mental States (CAARMS) and the 
Structured Interview for Psychosis-Risk Syndrome (SIPS). The authors of The Psychosis-
Risk Syndrome Handbook for Diagnosis and Follow-up and the developers of the SIPS 
tool explain the differences between these two assessment tools: 
CAARMS was originally crafted to be a diagnostic instrument.  The SIPS 
on the other hand was designed to diagnose not only the risk syndromes 
but also the presence of or conversion to psychosis, and to rate the severity 
of risk symptoms longitudinally, i.e., to measure change with time and 
treatments.  (McGlashan et al., 2010, p. 16) 
 The SIPS provides a clinician the ability to assess for APS symptoms as well as to 
rate the severity of the symptoms. The formal and lengthy process of administering the 
SIPS could be a challenge to the development of the therapeutic alliance.  
 Early intervention has shown to be invaluable in alleviating and reducing trauma 
experienced by a patient with APS symptoms. However, various tools can only be 
effective to use in assessing APS symptoms if a patient is open and honest in their 
responses during an evaluation by a clinician and a therapeutic alliance has been 
established prior to the assessment.  This may be easier to establish with APS patients 
versus those with fully developed schizophrenia, as insight into their symptoms remains 
preserved. 
 Family members and friends that have a relationship with a patient experiencing 
APS symptoms can be resources to referring a patient to a clinician.  However, in some 
cases family members do not recognize their loved ones are experiencing APS symptoms 
(Ruston, 2010; Smiley, Plotch, Oppenheim, & Vine Street Pictures, 2006). In order for 
clinicians to recognize and assess a patient for APS it is necessary that the patient be 
evaluated with valid and reliable tools such as the SIPS.   
Sometimes fear and stigma exist that prevent a patient from being evaluated or 
sharing their psychosis experience with others (Smiley et al., 2006; Wong et al., 2009). It 
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takes insight, education, and awareness of changes in the behavior in a patient that can 
warrant an evaluation by a clinician.  Stigma and the negative effects on families and 
patients and the effect on early detection or assessment is challenging for clinicians 
because the clinicians are often not trained to recognize psychosis until it meets DSM 
criteria for schizophrenia. Therefore, accurate and early diagnosis of APS is important in 
placing the patient into the most effective treatment protocol whether it is schizophrenia 
or another cause of psychosis. An effective treatment strategy based upon an accurate 
diagnosis is critical for the best outcome. 
Despite the advantages of early recognition, there are also risks that all mental 
health clinicians, including professional counselors, should be aware of when working 
with this population.  A diagnosis of APS, accurate or not, may result in a referral to a 
physician whom may prescribe high dose medications. The popular wisdom that high 
dose antipsychotic medications are the obvious choice for people experiencing APS 
symptoms, based on their effectiveness with those patients who met full diagnostic 
criteria for schizophrenia, may have iatrogenic consequences.  Alternative psychosocial 
counseling interventions may be more appropriate for patients with APS symptoms 
(Kane, Krystal, & Correll, 2003).  Bentall and Morrison (2002) suggested that the use of 
antipsychotic medications at all might be dangerous because of the aversive side effects.  
Further, their effect on the developing brain of adolescents, the age in which APS criteria 
is most likely to be met, is yet unknown (Bola, Kao, & Soydan, 2011).  
 Counselors may offer strength in the areas of accurate empathy and rapport 
building for patients with APS symptoms. Diagnostic training is crucial for APS and is 
limited at this time (Council for Accreditation of Counseling & Related Educational 
Programs, 2011).  It is essential for counselors to receive postgraduate training on early 
recognition tools such as the SIPS to aid in proper diagnosis, and ultimately treatment, 
which maximizes benefits and minimizes risks for the patient.   
 Any assessment tool could be ineffective, regardless of training if a patient is not 
willing to seek professional attention.  As a greater goal, our culture might work toward 
minimizing any existing negative stigmas regarding schizophrenia and toward 
encouraging accurate early recognition of symptoms.  There is a sense of great optimism 
and hope in the research being done today on APS, that this greater goal may be reached; 
hence, the consideration for this diagnosis as a new category in the DSM-5.  The hope is 
the final decision on inclusion of APS has the desired effect of early recognition and 
more appropriate treatment as opposed to misdiagnosis and further perpetuation of an 
already poorly understand condition.  Properly trained and sensitive counselors may be 
helpful in achieving this goal. 
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Table 1.  
Scale of Psychosis Risk Syndrome (SOPS) 
Sections of the SOPS Subsections Measures Summary 
Positive symptoms 1. Unusual thought content/ 
Delusional Ideas 
2. Suspiciousness/Persecutory 
Ideas 
3. Grandiose Ideas 
4. Perceptual 
Abnormalities/Hallucinations 
5. Disorganized Communication 
Several interview questions 
are asked by the clinician to 
the patient requiring a “N” or 
no, “NI”=no information, or 
“Y” yes response. 
 
If a “Y” response is given for a 
question additional questions 
are asked to obtain more 
information. 
 
Two types of severity scales:  
 
1. For positive symptoms 
ranging from 0 
(absent) to 6 (severe 
and psychotic)  
 
2. For negative, 
disorganized and 
general symptoms 
ranging from 0 
(absent) to 6 
(Extreme) 
The total combined SOPS score for the four 
sections do not affect the diagnosis of PRS 
but are taken to quantify the range and 
severity of the PRS symptoms. The SOPS 
scales are used in the COPS and POPS 
sections of the SIPS. 
 
Number of questions requiring a “Y,N,NI” 
response per section: 
Positive Symptoms:  48 
Negative Symptoms: 13 
Disorganization Symptoms: 9 
General Symptoms: 4 
 
 
Number of Severity Scale questions 
administered per section:  
 
Positive Symptoms:  5 
Negative Symptoms: 6 
Disorganization Symptoms: 4 
General Symptoms: 4 
 
Negative symptoms 1. Social Anhedonia 
2. Avolition 
3. Expression of Emotions and 
Self 
4. Experience of Emotions and 
Self 
5. Ideational Richness 
6. Occupational Functioning 
Disorganization 
symptoms 
1. Odd Behavior of Appearance 
2. Bizarre Thinking 
3. Trouble with Focus and 
Attention 
4. Impairment in Personal 
Hygiene 
General symptoms 1. Sleep Disturbance 
2. Dysphoric Mood 
3. Motor Disturbances 
4. Impaired Tolerance to Normal 
Stress 
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Table 2.  
Presence of Psychotic Symptoms Criteria (POPS) 
Assessment types Measures Summary 
Initial screening (pre-POPS) Intuitive freedom given to a trained clinician to assess for 
psychosis in the past or present.  Questions would 
include but are not limited to history of trauma, abuse, 
learning disability, developmental history, substance 
abuse, recent changes, family history of psychosis, and 
any extraordinary life circumstances. 
Clinicians can rule out current and past 
episodes of psychosis and should not 
use the SIPS if a patient meets these 
criteria. 
Positive Symptoms scale for 
SOPS and 
Frequency/Duration/Urgency 
1. The patient scores “6” on any one of the SOPS 
positive symptoms questions.  
2. At least one symptom above has occurred for over 
one month at a minimum frequency of four days per 
week and one hour of those days. 
A positive assessment for a current or 
past psychosis requires both measures 
to be met. 
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Table 3. 
Criteria of Psychosis-Risk Syndrome (COPS) 
Types of PRS 
Length or frequency of 
symptoms 
Measures Summary 
Brief Intermittent 
Psychotic Syndrome 
(BIPS):  Psychotic 
symptoms that are very 
brief and recent. 
Began in the past three 
months, is present 
several minutes in one 
day with a frequency of 
at least once per month. 
1. The patient scores “6” on any one of the 
SOPS Positive Symptoms section questions.  
2.  If any of the “6” scores have occurred in 
the last three months.  
3.  If both of the above have occurred for at 
least several minutes in one day at least 
once this month.   
4. Lastly that the patient does not better fit into 
any other AXIS I or II DSM IV diagnosis. 
The patient would be diagnosed 
with BIPS if they met the four 
condition measures. 
Attenuated Positive 
Symptom Syndrome 
(APSS): Positive 
attenuated psychosis-risk 
level symptoms that are 
severe and frequent. 
Began in the past year 
or rates on a scale of 
severity that is one 
level higher than 12 
months ago, frequency 
of at least once per 
week in the past month 
at the current level of 
intensity. 
1. The patient scores “3-5” on any one of the 
SOPS positive symptoms questions.   
2. If any of the “3-5” scores begun within the 
past year or currently rate one point higher 
than last year.   
3. If both of the above have occurred at least 
once per week in the past month.   
4. The patient does not better fit into a DSM-
IV AXIS I or II disorder. 
A diagnosis of APSS would be 
given if the patient meets the 
four criteria measures. 
Genetic Risk and 
Deterioration Syndrome 
(GRDS): Combined 
genetic risk for a 
schizophrenic disorder 
and a recent 
deterioration of 
functionality. 
Functional deterioration 
in the last month. 
1. First-degree relative has had a psychotic 
disorder or the patient meets criteria for 
Schizotypal Personality disorder based on 
the DSM-IV.  
2. A current 30% drop in GAF, taken from the 
DSM-IV, scores relative to the highest GAF 
in the last 12 months. 
A positive diagnosis for GRDS 
would be given if both 
measures are met. 
 
 
